Primary Care Prescribing of Anti-Osteoporotic Type Medications Following Hospitalisation for Fractures

被引：0
|
作者：
McGowan, Bernie [1 ]
Casey, Miriam C. [2 ]
Marry, Joe [2 ]
Bennett, Kathleen [1 ]
机构：
[1] Trinity Ctr Hlth Sci, Pharmacol & Therapeut, Dublin 8, Ireland
[2] St James Hosp, Osteoporosis & Bone Hlth Clin, Dublin, Ireland
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2010年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
469
引用
收藏
页码：S198 / S198
页数：1
相关论文
共 50 条
  • [41] CAN ANTI-OSTEOPOROTIC THERAPY REDUCE ADJACENT FRACTURE IN MAGNETIC RESONANCE IMAGING-PROVEN ACUTE OSTEOPOROTIC VERTEBRAL FRACTURES?
    Chen, Y. -C.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1176 - 1177
  • [42] Recent Trends in the Prescribing of ADHD Medications in Canadian Primary Care
    Morkem, Rachael
    Patten, Scott
    Queenan, John
    Barber, David
    JOURNAL OF ATTENTION DISORDERS, 2020, 24 (02) : 301 - 308
  • [43] Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis
    Saito, T.
    Sterbenz, J. M.
    Malay, S.
    Zhong, L.
    MacEachern, M. P.
    Chung, K. C.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 (12) : 3289 - 3300
  • [44] Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis
    T. Saito
    J. M. Sterbenz
    S. Malay
    L. Zhong
    M. P. MacEachern
    K. C. Chung
    Osteoporosis International, 2017, 28 : 3289 - 3300
  • [45] Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997-2006
    Abrahamsen, B.
    Vestergaard, P.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 (03) : 373 - 380
  • [46] Under-prescribing of prophylactic oral bisphosphonate therapy for osteoporotic type fractures
    Bennett, Kathleen
    McGowan, Bernadette
    Feely, John
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S73 - S73
  • [47] Under-prescribing of prophylactic oral bisphosphonate therapy for osteoporotic type fractures
    Bennett, K.
    McGowan, B.
    Feely, J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 (07) : 742 - 743
  • [48] Sustained anti-osteoporotic action of risedronate compared to anti-RANKL antibody following discontinuation in ovariectomized mice
    Omiya, Toshinobu
    Hirose, Jun
    Omata, Yasunori
    Tominari, Tsukasa
    Inada, Masaki
    Watanabe, Hisato
    Miyamoto, Takeshi
    Tanaka, Sakae
    BONE REPORTS, 2020, 13
  • [49] Trends in anti-osteoporotic medication utilization following fragility fracture in the USA from 2011 to 2019
    Amil R. Agarwal
    Jordan S. Cohen
    Alexis Jorgensen
    Savyasachi C. Thakkar
    Umasuthan Srikumaran
    Gregory J. Golladay
    Osteoporosis International, 2023, 34 : 379 - 385
  • [50] Trends in anti-osteoporotic medication utilization following fragility fracture in the USA from 2011 to 2019
    Agarwal, Amil R.
    Cohen, Jordan S.
    Jorgensen, Alexis
    Thakkar, Savyasachi C.
    Srikumaran, Umasuthan
    Golladay, Gregory J.
    OSTEOPOROSIS INTERNATIONAL, 2023, 34 (02) : 379 - 385
12345